• It’s a small world

    To understand the full scope of a condition, pharma needs to appreciate the full tapestry of the patient experience. The challenge for industry in the realm of rare diseases, however, is to meaningfully engage with patients and convince them that they are an essential part of the research equation

  • Changing tack

    Think the old product launch playbook is still relevant? Think again.

  • The strongest link?

    Jennifer Bradford and Matthew Metherell consider the success and potential of artificial intelligence in clinical research and the impact of machine learning on clinical trials

News

View all
Thumbnail image for EU nod for Bayer's Vitrakvi

EU nod for Bayer's Vitrakvi

European regulators have cleared Bayer's Vitrakvi (larotrectinib) as a treatment for solid tumours displaying an NTRK gene fusion.

23rd September 2019

Web Exclusives

View all
Thumbnail image for Engaging with patient advocacy groups

Engaging with patient advocacy groups

Harrison Gaiger, marketing manager of the Research Partnership, says working with patient advocacy groups is key to conducting effective rare disease research

Thumbnail image for It’s a small world

It’s a small world

To understand the full scope of a condition, pharma needs to appreciate the full tapestry of the patient experience. The challenge for industry in the realm of rare diseases, however, is to meaningfully engage with patients and convince them that they are an essential part of the research equation

Thumbnail image for The liberation of patient data

The liberation of patient data

Aiden Flynn explores how the collection and analysis of real-world patient data can be an invaluable asset in clinical development

Thumbnail image for Changing tack

Changing tack

Think the old product launch playbook is still relevant? Think again.

Thumbnail image for Making sense of it

Making sense of it

As life sciences companies’ international ambitions grow, and global regulatory scrutiny in parallel, managing translated content is becoming ever more complex. So the promise of neural machine learning as a potential solution is appealing. But just how far can the technology go in reducing workloads and improving accuracy and turnaround times?

Thumbnail image for The promise of gene editing

The promise of gene editing

Christopher Vakulskas says the rapid progress seen in gene editing is exciting, but there are still challenges in the field to overcome if its full potential is to be reached

Thumbnail image for The strongest link?

The strongest link?

Jennifer Bradford and Matthew Metherell consider the success and potential of artificial intelligence in clinical research and the impact of machine learning on clinical trials

Thought Leadership

View all
Thumbnail image for New frontiers

New frontiers

Tom O'Leary considers how the Internet of Medical Things (IoMT) is evolving the patient role in pharma

Thumbnail image for A smart and healthy approach to defending the bottom line

A smart and healthy approach to defending the bottom line

New smart building technologies are helping pharmaceutical companies enhance productivity without compromising on compliance or quality. However, to maximise the available opportunities, companies need to choose the right technology providers, explains Adam Chapman, Vertical Sales Director – Life Sciences (Europe) at Honeywell Building Solutions.

Webinars

View all

Designing Pharma organisations for success

Across all industries, people are changing the ways they engage with products, services, and brands. View more...

Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download